See more : ClimateRock (CLRCR) Income Statement Analysis – Financial Results
Complete financial analysis of Arovella Therapeutics Limited (ALA.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arovella Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- TOCALO Co.,Ltd. (3433.T) Income Statement Analysis – Financial Results
- Big Rock Brewery Inc. (BR.TO) Income Statement Analysis – Financial Results
- Kier Group plc (KIE.L) Income Statement Analysis – Financial Results
- Interhides Public Company Limited (IHL.BK) Income Statement Analysis – Financial Results
- Kuraray Co., Ltd. (KURRF) Income Statement Analysis – Financial Results
Arovella Therapeutics Limited (ALA.AX)
About Arovella Therapeutics Limited
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.00K | 405.90K | 295.81K | 257.35K | 532.69K | 1.22M | 425.86K | 7.22M | 5.79M | 5.62M | 8.65M | 4.05M | 3.91M | 3.00M | 14.22K | 19.35K | 11.86M | 9.51M | 8.34M | 8.17M | 4.75M | 140.77K | 0.00 | 0.00 |
| Cost of Revenue | 42.98K | 3.41M | 207.06K | 222.75K | 200.97K | 199.69K | 185.62K | 5.48M | 4.62M | 5.02M | 6.07M | 3.21M | 3.24M | 2.54M | 0.00 | 69.01K | 8.05M | 6.37M | 3.79M | 4.99M | 2.42M | 78.16K | 0.00 | 0.00 |
| Gross Profit | -25.98K | -3.00M | 88.75K | 34.60K | 331.72K | 1.02M | 240.24K | 1.74M | 1.17M | 601.93K | 2.58M | 833.88K | 665.38K | 465.03K | 14.22K | -49.66K | 3.81M | 3.14M | 4.55M | 3.18M | 2.32M | 62.61K | 0.00 | 0.00 |
| Gross Profit Ratio | -152.82% | -739.07% | 30.00% | 13.44% | 62.27% | 83.62% | 56.41% | 24.14% | 20.16% | 10.70% | 29.84% | 20.61% | 17.02% | 15.48% | 100.00% | -256.59% | 32.13% | 33.05% | 54.59% | 38.93% | 48.95% | 44.48% | 0.00% | 0.00% |
| Research & Development | 6.74M | 3.98M | 2.60M | 541.55K | 228.78K | 6.68M | 618.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.17K | 46.28K | 0.00 | 0.00 |
| General & Administrative | 2.77M | 3.10M | 2.79M | 2.17M | 2.17M | 1.19M | 1.61M | 2.24M | 2.30M | 2.47M | 2.11M | 1.26M | 1.27M | 1.43M | 551.20K | 1.13M | 3.84M | 3.48M | 2.86M | 2.42M | 226.94K | 521.65K | 135.81K | 0.00 |
| Selling & Marketing | 1.28M | 433.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 133.38K | 362.42K | 191.13K | 346.50K | 311.55K | 236.78K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.05M | 2.70M | 2.79M | 2.17M | 2.17M | 1.19M | 1.61M | 2.24M | 2.30M | 2.47M | 2.11M | 1.26M | 1.27M | 1.43M | 551.20K | 1.26M | 4.20M | 3.67M | 3.21M | 2.73M | 463.71K | 521.65K | 135.81K | 0.00 |
| Other Expenses | 0.00 | 1.05M | 0.00 | 906.67K | 798.73K | 31.70K | 62.63K | 110.90K | -301.15K | 130.96K | -188.30K | 4.22K | 201.18K | 63.14K | 40.62K | 192.56K | 0.00 | 969.15K | 1.74M | -587.91K | -39.01K | -80.28K | -786.00K | 7.36K |
| Operating Expenses | 10.79M | 6.68M | 7.69M | 4.70M | 5.14M | 3.40M | 6.35M | 3.66M | 3.74M | 4.72M | 4.72M | 2.58M | 2.56M | 3.45M | 2.12M | 2.52M | 6.78M | 5.68M | 4.65M | 4.36M | 1.48M | 1.08M | 136.16K | 86.55K |
| Cost & Expenses | 10.83M | 10.09M | 7.89M | 4.92M | 5.34M | 3.60M | 6.53M | 9.14M | 8.36M | 9.74M | 10.79M | 5.79M | 5.80M | 5.99M | 2.12M | 2.59M | 14.83M | 12.05M | 8.44M | 9.36M | 3.90M | 1.15M | 136.16K | 86.55K |
| Interest Income | 138.74K | 30.02K | 3.85K | 6.54K | 43.51K | 30.80K | 2.53K | 24.02K | 85.81K | 102.77K | 104.98K | 20.61K | 93.08K | 80.14K | 21.06K | 7.13K | 56.86K | 70.92K | 96.33K | 133.97K | 155.77K | 49.51K | 36.00K | 0.00 |
| Interest Expense | 8.63K | 20.67K | 194.72K | 33.29K | 6.57K | 125.06K | 177.03K | 223.45K | 209.56K | 156.20K | 158.64K | 67.51K | 61.92K | 145.07K | 116.83K | 103.93K | 366.68K | 350.00K | 240.52K | 185.15K | 92.95K | 21.34K | 1.00K | 0.00 |
| Depreciation & Amortization | 42.98K | 837.18K | 551.49K | 652.18K | 572.38K | 471.13K | 157.46K | 97.58K | 122.36K | 123.65K | 67.15K | 33.57K | 55.82K | 95.51K | 70.16K | 78.73K | 687.76K | 371.53K | 158.68K | 409.54K | 349.85K | 166.63K | 345.00 | 0.00 |
| EBITDA | -8.83M | -10.37M | -7.87M | -4.99M | -3.40M | -8.12M | -6.44M | -1.83M | -2.72M | -3.70M | -2.02M | -1.74M | -4.62M | -4.17M | -4.42M | -2.80M | -8.58M | -1.33M | 425.27K | -1.33M | -525.04K | -876.94K | -750.00K | -86.55K |
| EBITDA Ratio | -51,959.76% | -2,178.76% | -2,380.28% | -1,204.88% | -638.99% | -151.51% | -1,381.58% | -23.30% | -46.17% | -66.88% | -22.78% | -41.81% | -39.43% | -91.57% | -13,864.57% | -11,855.00% | -18.77% | -11.10% | 1.83% | -16.33% | -11.06% | -622.97% | 0.00% | 0.00% |
| Operating Income | -10.81M | -9.68M | -7.59M | -3.75M | -3.98M | -2.32M | -6.04M | -1.81M | -2.79M | -3.89M | -2.04M | -1.72M | -1.60M | -2.85M | -2.04M | -2.37M | -2.91M | -1.43M | -6.40K | -1.74M | -874.90K | -1.04M | -750.35K | -86.55K |
| Operating Income Ratio | -63,595.65% | -2,385.02% | -2,566.71% | -1,458.30% | -746.44% | -190.16% | -1,418.55% | -25.02% | -48.28% | -69.08% | -23.56% | -42.64% | -40.85% | -94.75% | -14,358.16% | -12,261.79% | -24.57% | -15.01% | -0.08% | -21.34% | -18.44% | -741.34% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.07M | -1.55M | -1.02M | -1.29M | -2.93M | -1.76M | -4.69M | -223.45K | -1.28M | 44.37K | -241.96K | -63.29K | -2.70M | -1.52M | -1.59M | -286.93K | -6.08M | 972.50K | 1.58M | -185.15K | -92.95K | 78.40K | -995.00 | 7.36K |
| Income Before Tax | -8.75M | -11.23M | -8.62M | -5.05M | -9.94M | -8.72M | -6.78M | -2.03M | -3.03M | -4.04M | -2.24M | -1.84M | -4.60M | -4.51M | -3.69M | -2.86M | -9.21M | -1.77M | -265.99K | -1.93M | -967.85K | -1.06M | -751.00K | -79.19K |
| Income Before Tax Ratio | -51,447.26% | -2,766.73% | -2,914.23% | -1,961.35% | -1,866.73% | -715.29% | -1,591.61% | -28.12% | -52.38% | -71.76% | -25.92% | -45.53% | -117.55% | -150.11% | -25,981.21% | -14,776.20% | -77.71% | -18.65% | -3.19% | -23.60% | -20.39% | -756.50% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.05M | 194.72K | 939.96K | 805.30K | -925.00K | -745.00K | -792.00K | -800.00K | -657.92K | -180.37K | -174.22K | 263.10K | 208.21K | 1.32M | 439.60K | 352.65K | 1.39M | 237.63K | -1.93M | -967.85K | -1.06M | -751.00K | -79.19K |
| Net Income | -8.75M | -10.18M | -8.62M | -5.05M | -9.94M | -7.80M | -5.46M | -1.24M | -2.23M | -3.37M | -2.05M | -1.67M | -4.60M | -4.51M | -4.86M | -3.00M | -9.20M | -1.77M | -265.99K | -1.93M | 0.00 | -1.06M | -751.00K | -79.19K |
| Net Income Ratio | -51,447.26% | -2,508.35% | -2,914.23% | -1,961.35% | -1,866.73% | -639.42% | -1,281.93% | -17.15% | -38.56% | -59.86% | -23.73% | -41.22% | -117.55% | -150.11% | -34,163.29% | -15,515.69% | -77.59% | -18.65% | -3.19% | -23.60% | 0.00% | -756.50% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.06 | -0.07 | -0.08 | -0.02 | -0.04 | -0.06 | -0.05 | -0.05 | -0.14 | -0.18 | -0.25 | -0.28 | -0.87 | -0.20 | -0.03 | -0.26 | -0.14 | -0.20 | -0.16 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.06 | -0.07 | -0.08 | -0.02 | -0.04 | -0.06 | -0.05 | -0.05 | -0.13 | -0.18 | -0.25 | -0.28 | -0.87 | -0.20 | -0.03 | -0.26 | -0.14 | -0.20 | -0.16 | -0.01 |
| Weighted Avg Shares Out | 941.42M | 711.48M | 549.62M | 330.89M | 167.91M | 116.36M | 66.23M | 62.67M | 61.78M | 55.07M | 45.32M | 33.13M | 32.23M | 25.57M | 19.33M | 10.81M | 10.56M | 8.97M | 7.76M | 7.44M | 6.96M | 5.38M | 4.73M | 6.16M |
| Weighted Avg Shares Out (Dil) | 941.42M | 711.48M | 549.62M | 330.89M | 167.91M | 116.36M | 66.23M | 62.67M | 61.78M | 55.07M | 45.32M | 33.13M | 34.37M | 25.57M | 19.33M | 10.81M | 10.56M | 8.97M | 7.83M | 7.44M | 6.96M | 5.38M | 4.73M | 6.16M |
Source: https://incomestatements.info
Category: Stock Reports